Published in J Am Coll Cardiol on April 16, 2003
Risk Markers in the Acute Coronary Syndromes (RACS) | NCT00521976
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J (2008) 1.88
Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass grafting. Anesthesiology (2009) 1.85
Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart (2012) 1.47
Value of N-terminal pro brain natriuretic peptide in predicting prognosis and severity of coronary artery disease in acute coronary syndrome. J Saudi Heart Assoc (2014) 1.24
The paradox of low BNP levels in obesity. Heart Fail Rev (2012) 1.23
Biomarkers in acute myocardial infarction. BMC Med (2010) 1.22
Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev (2007) 1.16
Preoperative B-type natriuretic peptide is as independent predictor of ventricular dysfunction and mortality after primary coronary artery bypass grafting. J Thorac Cardiovasc Surg (2008) 1.06
Cardioprotective actions of peptide hormones in myocardial ischemia. Heart Fail Rev (2007) 1.02
Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol (2007) 0.92
B-type natriuretic peptide and high sensitive C-reactive protein predict 2-year all cause mortality in chest pain patients: a prospective observational study from Salta, Argentina. BMC Cardiovasc Disord (2011) 0.92
Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. Eur Heart J (2011) 0.86
B-type natriuretic peptide is a long-term predictor of all-cause mortality, whereas high-sensitive C-reactive protein predicts recurrent short-term troponin T positive cardiac events in chest pain patients: a prognostic study. BMC Cardiovasc Disord (2008) 0.85
Plasma Brain Natriuretic Peptide (BNP) as an Indicator of Left Ventricular Function, Early Outcome and Mechanical Complications after Acute Myocardial Infarction. Clin Med Insights Cardiol (2011) 0.83
Vitamin d predicts all-cause and cardiac mortality in females with suspected acute coronary syndrome: a comparison with brain natriuretic Peptide and high-sensitivity C-reactive protein. Cardiol Res Pract (2013) 0.82
B-type natriuretic peptide levels predict extent and severity of coronary artery disease in non-ST elevation acute coronary syndrome and normal left ventricular function. Indian Heart J (2013) 0.82
Prognostic value of brain natriuretic peptide in patients with heart failure and reserved left ventricular systolic function. Exp Ther Med (2014) 0.82
Association of 25-hydroxyvitamin D deficiency with NT-pro BNP levels in patients with acute myocardial infarction: a cross-sectional analysis. BMC Res Notes (2011) 0.82
Peak systolic velocity using color-coded tissue Doppler imaging, a strong and independent predictor of outcome in acute coronary syndrome patients. Cardiovasc Ultrasound (2013) 0.81
Best evidence topic report. Brain natriuretic peptide as a potential marker of acute coronary syndromes. Emerg Med J (2006) 0.81
A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes. Clin Res Cardiol (2006) 0.81
N-terminal pro-brain natriuretic peptide could be a marker of subclinical atherosclerosis in patients with type 2 diabetes. Heart Vessels (2012) 0.81
B-Type Natriuretic Peptide (BNP) and Left Ventricular (LV) Function in Patients with ST-Segment Elevation Myocardial Infarction (STEMI). Maedica (Buchar) (2010) 0.79
A Novel Risk Stratification Model for Patients with Non-ST Elevation Myocardial Infarction in the Korea Acute Myocardial Infarction Registry (KAMIR): Limitation of the TIMI Risk Scoring System. Chonnam Med J (2011) 0.79
Acute coronary syndromes: from the laboratory markers to the coronary vessels. Biomark Insights (2007) 0.78
Temporal cardiac remodeling post-myocardial infarction: dynamics and prognostic implications in personalized medicine. Heart Fail Rev (2015) 0.78
The standards for reporting diagnostic accuracy studies 2015 update: is there a missing link to the triumvirate? Ann Transl Med (2016) 0.78
Early diagnosis of rats with acute myocardial infarction by measurement of brain natriuretic peptide. Exp Ther Med (2013) 0.78
Prediction of clinical outcome in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) using the TIMI risk score extended by N-terminal pro-brain natriuretic peptide levels. Wien Klin Wochenschr (2007) 0.77
Patients at risk. Recent study findings on predicting and improving outcomes. Rev Cardiovasc Med (2003) 0.75
Very Long-Term Prognostic Role of Admission BNP in Non-ST Segment Elevation Acute Coronary Syndrome. Arq Bras Cardiol (2016) 0.75
A Comparison of Prognostic Value of the Levels of ProBNP and Troponin T in Patients with Acute Coronary Syndrome (ACS). Med Arch (2016) 0.75
Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity. Oncol Lett (2016) 0.75
B-type natriuretic peptide release in the coronary effluent after acute transient ischaemia in humans. Heart (2007) 0.75
Diagnostic markers of acute myocardial infarction. Biomed Rep (2015) 0.75
Borderline Values of Troponin-T and High Sensitivity C-Reactive Protein Did Not Predict 2-Year Mortality in TnT Positive Chest-Pain Patients, Whereas Brain Natriuretic Peptide Did. Front Cardiovasc Med (2015) 0.75
Correlation between brain natriuretic peptide levels and the prognosis of patients with left ventricular diastolic dysfunction. Exp Ther Med (2016) 0.75
Prognostic Biomarkers in Acute Coronary Syndromes: Risk Stratification Beyond Cardiac Troponins. Curr Cardiol Rep (2017) 0.75
Metabolic Syndrome is Associated With Higher Wall Motion Score and Larger Infarct Size After Acute Myocardial Infarction. Res Cardiovasc Med (2015) 0.75
Multimarker risk stratification approach and cardiovascular outcomes in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention. Indian Heart J (2016) 0.75
Acute coronary syndrome in the older adults. J Geriatr Cardiol (2016) 0.75
[Biomarkers in cardiology--state of the art 2007]. Wien Med Wochenschr (2007) 0.75
Natriuretic peptide hormone measurement in acute coronary syndromes. Heart Fail Rev (2003) 0.75
Non-contrast cardiac CT immediately after percutaneous coronary intervention: does it predict the risk of left ventricular remodeling in patients with ST-elevation myocardial infarction? Int J Cardiovasc Imaging (2016) 0.75
Bariatric surgery: a systematic review and meta-analysis. JAMA (2004) 23.34
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med (2014) 8.61
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med (2003) 7.25
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA (2010) 5.37
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28
Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med (2009) 5.19
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA (2012) 4.92
Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation (2011) 4.78
2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2014) 4.57
A tale of coronary artery disease and myocardial infarction. N Engl J Med (2012) 4.53
Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol (2008) 4.51
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (2010) 4.46
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (2009) 4.31
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol (2006) 4.16
Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med (2005) 4.13
Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10
Diabetes and mortality following acute coronary syndromes. JAMA (2007) 4.09
Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA (2012) 4.04
Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation (2008) 4.00
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (2015) 3.79
The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med (2004) 3.78
Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA (2005) 3.72
Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA (2012) 3.71
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med (2006) 3.56